Geriatric use information added to precautions section of labeling for the blood-glucose lowering agent glimepiride. The subsection, approved Sept. 27, reports no differences in safety or effectiveness between patients over 65 and those under 65, but caution is advised in dose selection as "the risk of toxic reactions to this drug may be greater in patients with impaired renal function," which is more common in elderly patients. Renal monitoring is suggested, along with blood glucose monitoring
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth